Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BVs Need Efficient Reorganization: Mr Iwatani of Kringle Pharma
July 2, 2007
- Banyu to Boost Promotion of Once-Weekly Fosamac
July 2, 2007
- Astellas Launches Advagraf in the UK, Germany
July 2, 2007
- Takeda to Consolidate Its Top Position with Once-Weekly Risedronate Formulation
July 2, 2007
- Eisai Launches Inovelon in Europe
July 2, 2007
- NEW PRODUCTS／Otsuka: Pletaal Powder 20% That Can Be Taken without Water
July 2, 2007
- Toyama Licenses T-5224 to Roche
July 2, 2007
- BUSINESS NEWS IN BRIEF
July 2, 2007
- Teijin to Boost Market Share in the Field of Bone Treatment
July 2, 2007
- FPMAJ Subcommittees Present Reports on Drug Pricing Reform
July 2, 2007
- Clinical, Commercialization Research to Receive Priority in FY2008 Budgeting: Mr Araki
July 2, 2007
- Chugai to Conduct Studies to Clarify Causal Relationship between Tamiflu and Abnormal Behavior
July 2, 2007
- REGULATORY NEWS IN BRIEF
July 2, 2007
- JGPMA Presents Its Proposal to the FPMAJ
July 2, 2007
- Physicians Need Reliable Brands: FPMAJ Survey
July 2, 2007
- GENERICS NEWS IN BRIEF
July 2, 2007
- R&D NEWS IN BRIEF
July 2, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 2, 2007
- TOPICS 3 articles
July 2, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…